Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
Cottu P, Cheeseman S, Hall P, Wöckel A, Scholz CW, Bria E, Orlandi A, Ribelles N, Vallet M, Niklas N, Hogg C, Aggarwal S, Moreira J, Lucerna M, Collin SM, Logue A, Long GH. Cottu P, et al. Among authors: orlandi a. Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506-4. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39427280
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G, Carbognin L, Arcanà C, Parola S, Ventriglia A, Doronzo A, Garutti M, Orlandi A, Palazzo A, Fabi A, Bria E, Tortora G, Arpino G, Giuliano M, Del Mastro L, De Laurentiis M, Puglisi F. Garufi G, et al. Among authors: orlandi a. Cancer Treat Rev. 2022 Nov;110:102454. doi: 10.1016/j.ctrv.2022.102454. Epub 2022 Aug 11. Cancer Treat Rev. 2022. PMID: 35987149 Review.
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis.
Mastrantoni L, Giordano G, Vita E, Horn G, Russo J, Orlandi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: orlandi a. Cancer Treat Res Commun. 2024;41:100842. doi: 10.1016/j.ctarc.2024.100842. Epub 2024 Sep 6. Cancer Treat Res Commun. 2024. PMID: 39260066 Free article. Review.
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L, Orlandi A, Palazzo A, Garufi G, Fabi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: orlandi a. EClinicalMedicine. 2023 Jan 20;56:101824. doi: 10.1016/j.eclinm.2023.101824. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36713467 Free PMC article.
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Orlandi A, Mastrantoni L, Bria E, Tortora G. Orlandi A, et al. Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3. Ann Oncol. 2024. PMID: 38838845 No abstract available.
532 results